VBIO - Vitality Biopharma, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.6200
-0.0800 (-11.43%)
At close: 3:21PM EST
Stock chart is not supported by your current browser
Previous Close0.7000
Open0.0000
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0000 - 0.0000
52 Week Range
Volume0
Avg. Volume144,600
Market Cap22.537M
Beta (3Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.19
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.40
Trade prices are not sourced from all markets
  • GlobeNewswire16 days ago

    Vitality Biopharma to Present at the 11th Annual LD Micro Main Event

    Vitality Biopharma, Inc. (VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will be presenting at the 11th Annual LD Micro Main Event in Los Angeles. The corporate presentation is on Wednesday, December 5, 2018 at 12:00 PM Pacific/3:00 PM Eastern. Mr. Robert Brooke, CEO of Vitality, will be giving the presentation and meeting with investors during the event.

  • GlobeNewswire28 days ago

    Vitality Biopharma Announces Corporate Updates and Completion of an SEC Examination

    Company appoints two new directors including the Hon. LOS ANGELES, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (VBIO) (“Vitality Biopharma”, “Vitality”, or the “Company”), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced corporate updates, the appointment of two new directors including a new Chairman of the Board, and the completion of an SEC examination.

  • ACCESSWIRElast month

    SeeThruEquity Issues Update on Vitality Biopharma (VBIO) with Target Price of $3.50

    NEW YORK, NY / ACCESSWIRE / November 7, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update note on Vitality Biopharma, Inc. (VBIO) with a Target Price of $3.50. Vitality Biopharma, Inc. (OTCQB: VBIO, ''Vitality'') is focused on the development of cannabinoids for the treatment of serious neurological and inflammatory disorders, as well as pain and opioid addiction. Vitality's development pipeline is focused on a new class of cannabinoid prodrug pharmaceuticals called cannabosides.

  • ACCESSWIRE2 months ago

    Vitality Biopharma Tackling the Medical Benefits of Cannabis with a Diverse Pipeline

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Vitality Biopharma, Inc. (VBIO), a cure development company, dedicated to unlocking the power of cannabinoid "prodrugs" as a means to treat serious neurological and inflammatory disorders.

  • GlobeNewswire3 months ago

    Vitality Biopharma Announces Neural Repair Treatment Patent Filings

    LOS ANGELES, Oct. 03, 2018 -- Vitality Biopharma, Inc. (OTCQB: VBIO) (“Vitality” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug.

  • ACCESSWIRE10 months ago

    The Story Behind Growth: New Report Discusses Vitality Biopharma and Growlife - Emerging Trends Within New Industry

    NEW YORK, NY / ACCESSWIRE / February 28, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of Vitality Biopharma, Inc. ( OTCQB: VBIO ) and Growlife, Inc. ( ...

  • ACCESSWIRE11 months ago

    SeeThruEquity Issues Update on Vitality Biopharma, Inc. (VBIO)

    NEW YORK, NY / ACCESSWIRE / January 30, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...